Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, MD, FRCOG, Joachim W.

Ed. by Bancalari, Eduardo / Chappelle, Joseph / Chervenak, Frank A. / D'Addario , Vincenzo / Genc, Mehmet R. / Greenough, Anne / Grunebaum, Amos / Konje, Justin C. / Kurjak M.D., Asim / Romero, Roberto / Zalud, MD PhD, Ivica

IMPACT FACTOR 2018: 1.361
5-year IMPACT FACTOR: 1.578

CiteScore 2018: 1.29

SCImago Journal Rank (SJR) 2018: 0.522
Source Normalized Impact per Paper (SNIP) 2018: 0.602

See all formats and pricing
More options …
Volume 47, Issue 7


The sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets as compared to perinatal outcomes

Magdalena Bednarek-JędrzejekORCID iD: https://orcid.org/0000-0002-4006-7774 / Sebastian Kwiatkowski / Joanna Ksel-Hryciów / Piotr Tousty / Karolina Nurek / Ewa Kwiatkowska
  • Department of Nephrology, Transplantology and Internal Medicine, Pomeranian Medical University, Szczecin, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Aneta Cymbaluk-Płoska
  • Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Andrzej Torbé
Published Online: 2019-07-24 | DOI: https://doi.org/10.1515/jpm-2019-0019



Soluble fms-like tyrosine kinase-1 (sFlt-1) and placental growth factor (PlGF) are used as markers of preeclampsia. The aim of this paper was to assess the correlations between the sFlt-1/PlGF ratio values within the <38, 38–85 and >85 brackets and perinatal outcomes in pregnancies that require determination of these markers.


A total of 927 pregnant patients between 18 and 41 weeks’ gestation suspected of or confirmed with any form of placental insufficiency (preeclampsia, intrauterine growth restriction [IUGR], gestational hypertension, HELLP syndrome, placental abruption) were included in the study. In each of the patients, the sFlt-1/PlGF ratio was calculated. Patients were divided into three groups according to the sFlt-1/PlGF ratio brackets of <38, 38–85 and >85.


Significantly worse perinatal outcomes were found in the sFlt-1/PlGF >85 group, primarily with lower cord blood pH, neonatal birth weight and shorter duration of gestation. Statistically significant correlations between the values of these markers and the abovementioned perinatal effects were found.


An sFlt-1/PlGF ratio value of >85 suggests that either preeclampsia or one of the other placental insufficiency forms may occur, which is associated with lower cord blood pH, newborn weight and earlier delivery. Determining the disordered angiogenesis markers and calculating the sFlt-1/PlGF ratio in pregnancies complicated by placental insufficiency may lead to better diagnosis, therapeutic decisions and better perinatal outcomes.

Keywords: fms-like tyrosine kinase-1(sFlt-1); perinatal outcome; placental growth factor (PlGF); placental insufficiency


  • 1.

    Maynard SE, Karumanchi SA. Angiogenic factors and preeclampsia. Semin Nephrol 2011;31:33–46.CrossrefWeb of SciencePubMedGoogle Scholar

  • 2.

    Herraiz I, Simón E, Gómez-Arriaga PI, Martínez-Moratalla JM, García-Burguillo A, López Jiménez EA, et al. Angiogenesis-related biomarkers (sFlt-1/PLGF) in the prediction and diagnosis of placental dysfunction: an approach for clinical integration. Int J Mol Sci 2015;16:19009–26.CrossrefWeb of SciencePubMedGoogle Scholar

  • 3.

    Verlohren S, Stepan H, Dechend R. Angiogenic growth factors in the diagnosis and prediction of pre-eclampsia. Clin Sci 2012;122:43–52.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 4.

    Herraiz I, Llurba E, Verlohren S, Galindo A; Spanish Group for the Study of Angiogenic Markers in Preeclampsia. Update on the diagnosis and prognosis of preeclampsia with the aid of the sFlt-1/PlGF ratio in singleton pregnancies. Fetal Diagn Ther 2018;43:81–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 5.

    Stepan H, Herraiz I, Schlembach D, Verlohren S, Brennecke S, Chantraine F, et al. Implementation of the sFlt-1/PlGF ratio for prediction and diagnosis of pre-eclampsia in singleton pregnancy: implications for clinical practice. Ultrasound Obstet Gynecol 2015;45:241–6.CrossrefPubMedGoogle Scholar

  • 6.

    Magee LA, Kenny L, Ananth Karumanchi S, McCarthy F, Saito S, Hall DR, et al. The hypertensive disorders of pregnancy: ISSHP classification, diagnosis and management recommendations for international practice 2018. Preg Hyperten: Int J Women’s Cardiovasc Health 2018.Google Scholar

  • 7.

    German Guideline. 2015. Available at: http://www.awmf.org/uploads/tx_szleitlinien/015-018l_S1_Diagnostik_Therapie_hypertensiver_Schwangerschaftserkrankungen_2014-01.pdf. [Accessed January].

  • 8.

    National Collaborating Centre for Women’s and Children’s Health (UK). Hypertension in pregnancy: the management of hypertensive disorders during pregnancy. London: RCOG Press; NICE Clinical Guidelines, No. 107; 2010.Google Scholar

  • 9.

    Hund M, Schoedl M, Dilba P, Verhagen-Kamerbeek W, Stepan H. Multicenter prospective clinical study to evaluate the prediction of short-term outcome in pregnant women with suspected preeclampsia (PROGNOSIS): study protocol. BMC Preg Childbirth 2014;14:324.CrossrefGoogle Scholar

  • 10.

    Rana S, Powe CE, Salahuddin S, Verlohren S, Perschel FH, LevineRJ, et al. Angiogenic factors and the risk of adverse outcomes in women with suspected preeclampsia. Circulation 2012;125:911–9.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 11.

    Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cut-off values for the use of soluble fms-like tyrosine kinase-1/placental growth factor ratio as diagnostic test for preeclampsia. Hypertension 2014;63:346–52.CrossrefGoogle Scholar

  • 12.

    Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennström M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13–22.CrossrefWeb of SciencePubMedGoogle Scholar

  • 13.

    Chang YS, Chen CN, Jeng SF, Su YN, Chen CY, Chou HC, et al. The sFlt-1/PlGF ratio as a predictor for poor pregnancy and neonatal outcomes. Pediatr Neonatol 2017;58:529–33.CrossrefPubMedGoogle Scholar

  • 14.

    Masoura S, Kalogiannidis I, Makedou K, Theodoridis T, Koiou K, Gerou S, et al. Biomarkers of endothelial dysfunction in preeclampsia and neonatal morbidity: a case-control study. Eur J Obstet Gynecol Reprod Biol 2014;175:119–23.Web of SciencePubMedCrossrefGoogle Scholar

  • 15.

    Kwiatkowski S, Bednarek-Jędrzejek M, Ksel J, Tousty P, Kwiatkowska E, Cymbaluk A, et al. sFlt-1/PlGFand Doppler ultrasound parameters in SGA pregnancies with confirmed neonatal birth weight below10th percentile. Preg Hypertens 2018;14:79–85.CrossrefGoogle Scholar

  • 16.

    Shinohara S, Uchida Y, Kasai M, Sunami R. Association between the high soluble fms-like tyrosine kinase-1 to placental growth factor ratio and adverse outcomes in asymptomatic women with early-onset fetal growth restriction. Hypertens Preg 2017;36:269–75.CrossrefGoogle Scholar

  • 17.

    Valino N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 30–34 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 2016;47:194–202.PubMedCrossrefGoogle Scholar

  • 18.

    Valiño N, Giunta G, Gallo DM, Akolekar R, Nicolaides KH. Biophysical and biochemical markers at 35–37 weeks’ gestation in the prediction of adverse perinatal outcome. Ultrasound Obstet Gynecol 2016;47:203–9.PubMedCrossrefGoogle Scholar

  • 19.

    Saleh L, Vergouwe Y, van den Meiracker AH, Verdonk K, Russcher H, Bremer HA, et al. Angiogenic markers predict pregnancy complications and prolongation in preeclampsia continuous versus cutoff values. Hypertension 2017;70:1025–33.CrossrefPubMedWeb of ScienceGoogle Scholar

  • 20.

    Graupner O, Lobmaier SM, Ortiz JU, Karge A, Kuschel B. sFlt-1/PlGF ratio for the prediction of the time of delivery. Arch Gynecol Obstet 2018;298:567–77.CrossrefWeb of SciencePubMedGoogle Scholar

  • 21.

    Zeisler H, Llurba E, Chantraine FJ, Vatish M, Staff AC, Sennström M, et al. The sFlt-1/PlGF Ratio: ruling out pre-eclampsia for up to 4 weeks and the value of retesting. Ultrasound Obstet Gynecol 2018.Google Scholar

  • 22.

    Hoffmann J, Ossada V, Weber M, Stepan H. An intermediate sFlt-1/PlGF ratio indicates an increased risk for adverse pregnancy outcome. Preg Hypertens 2017;10:165–70.CrossrefGoogle Scholar

  • 23.

    Lecarpentier E, Tsatsaris V. Angiogenic balance (sFlt-1/PlGF) and preeclampsia. Annales d’Endocrinologie 2016;77:97–100.Web of SciencePubMedCrossrefGoogle Scholar

About the article

Received: 2019-01-18

Accepted: 2019-06-11

Published Online: 2019-07-24

Published in Print: 2019-09-25

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis, and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Journal of Perinatal Medicine, Volume 47, Issue 7, Pages 732–740, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: https://doi.org/10.1515/jpm-2019-0019.

Export Citation

©2019 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in